Pentedrone
α-propyl-N-methylcathinone
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Pentedrone (2-(methylamino)-1-phenylpentan-1-one) is a synthetic stimulant of the cathinone class. It sits between α-PVP and mephedrone in potency and selectivity.[1] Pentedrone is a dopamine and norepinephrine reuptake inhibitor, producing its effects by blocking the clearance of these neurotransmitters from the synapse.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, amphetamine, methamphetamine +2 morecocaine, amphetamine, methamphetamine, methylphenidate, other synthetic cathinones show less
Pentedrone first appeared on illicit markets in 2010 as a "bath salt" component, formally characterized by Maheux and Copeland in 2012.[3] It served as a scheduling-circumvention replacement for recently banned cathinones, becoming one of Europe's most-seized novel psychoactive substances by 2013. It is now controlled under UN Psychotropic Schedule II and US Schedule I.[4]
Subjective effects include stimulation, cognitive euphoria, motivation enhancement, and appetite suppression.[5] The experience is narrow-band and task-oriented — dopaminergic drive without the emotional warmth of serotonin-active cathinones, resembling cocaine's focused rush more than mephedrone's empathic character. Anxious overstimulation, compulsive redosing, and residual dysphoria are characteristic unsought effects.
Dependence liability is substantial — pentedrone induces conditioned place preference in animals,[1] and cardiovascular toxicity is the primary acute danger.[6] The short peak duration drives compulsive redosing that compounds cardiovascular strain and depletes dopamine, while in vitro liver toxicity exceeding that of MDMA raises concern for chronic users.[7] No controlled human studies exist; the current understanding rests on in vitro data, animal models, forensic cases, and structural analog extrapolation.
History[edit]
History
Discovery
Pentedrone appeared on illicit drug markets in 2010, sold as a "bath salt" component in the United States and United Kingdom. Its emergence followed the prohibition of mephedrone in the UK in April 2010,[8] part of a broader wave of synthetic cathinone novel psychoactive substances flooding Western markets. The first formal chemical characterization was published by Maheux and Copeland in 2012, providing full spectroscopic identification of the compound.[3]
Market evolution
Pentedrone's trajectory exemplifies the scheduling-circumvention cycle that defined early NPS markets. After the DEA emergency-scheduled methylone, mephedrone, and MDPV in 2011, at least one commercial vendor reformulated its product line to contain pentedrone as the unscheduled replacement.[9] By 2013, approximately 197 kg had been seized in Europe, placing pentedrone among the continent's most-intercepted synthetic cathinones alongside 3-MMC, 4-MEC, and α-PVP.[10]
Prohibition and modern status
International scheduling proceeded through the mid-2010s. The United States placed pentedrone in temporary emergency Schedule I in 2014,[11] extended in 2016,[12] and permanently scheduled it in 2017.[4] Following a WHO Expert Committee on Drug Dependence critical review in 2016, pentedrone entered UN Psychotropic Schedule II.[13] Wastewater studies in Slovakia,[14] hair testing in Paris,[15] and forensic casework in Hungary[16] confirm ongoing community-level use across Europe into the late 2010s.
The name "pentedrone" derives from its five-carbon ketone backbone ("pent-") and cathinone lineage ("-edrone"), following the systematic naming convention shared by methcathinone, buphedrone, and hexedrone. It circulated commercially under branded "bath salt" products — most notably "Raving Dragon Voodoo Dust," an explicitly marketed replacement for the recently scheduled methylone.[9]
Chemistry[edit]
Chemistry
Structural class
Pentedrone belongs to the synthetic cathinone family — β-keto phenethylamines derived from cathinone, the principal psychoactive alkaloid of the khat plant (Catha edulis). The core structure consists of a phenyl ring bearing a β-keto group, an N-methylamino group, and a propyl chain extending from the α-carbon. This propyl chain (yielding a five-carbon backbone, hence "pent-") distinguishes pentedrone from shorter-chain analogues like methcathinone (methyl) and buphedrone (ethyl), and from longer-chain compounds like hexedrone (butyl).
Among synthetic cathinones, DAT potency follows an inverted U-shaped relationship with side-chain length: potency peaks at the propyl chain (pentedrone and N-ethylpentedrone) and decreases with further extension.[17] The terminal amine substitution further modulates potency — pentedrone (N-methyl) is less potent than its N-ethyl analogue, and substantially less potent than pyrrolidine-substituted compounds such as α-PVP.[1]
Molecular properties
| Molecular formula | C₁₂H₁₇NO |
| Molecular weight | 191.27 g/mol |
The molecule features an unsubstituted phenyl ring, a β-carbonyl group, an N-methylamino substituent, and a propyl α-carbon side chain.[18]
Stereochemistry
Pentedrone has one chirality center at the α-carbon, producing two mirror-image forms: S-(+)-pentedrone and R-(-)-pentedrone. Illicit market samples contain the racemic mixture (equal mixture of both).[18] The S-(+) form shows greater toxicity to dopamine-producing neurons in cell studies, while the R-(-) form interacts more strongly with cellular efflux transporters.[19] No human studies comparing the enantiomers have been published.
Physical form
Pentedrone is typically encountered as a white crystalline powder in the hydrochloride salt form. Separating pentedrone from its eight positional isomers presents a significant forensic challenge, requiring specialized analytical techniques.[20]
Pharmacology[edit]
Pharmacology
Mechanism of action
Pentedrone blocks the reuptake of dopamine and norepinephrine without triggering their release from nerve terminals — a mechanism resembling cocaine and methylphenidate rather than amphetamine-type releasing agents.[2] It has minimal activity at the SERT,[1] which accounts for the absence of empathogenic or entactogenic effects.
One study has characterized pentedrone as both a DAT blocker and a serotonin transporter substrate — a "hybrid" property.[21] This conflicts with the majority of published data favoring a purely blocking profile.[2] The discrepancy may reflect differences in laboratory methods. The consensus position is that pentedrone acts primarily as a dopamine- and norepinephrine-selective reuptake inhibitor with negligible serotonin activity.[10]
Pharmacokinetics
No controlled human pharmacokinetic data exist for pentedrone. The best available estimates come from N-ethylpentedrone, the closest human-studied structural analog.
In a study administering 30 mg of N-ethylpentedrone intranasally to 6 participants, concentrations in oral fluid peaked within the first hour, with effects returning to baseline within 3–4 hours.[22][23] A clinical intoxication case found blood concentrations of N-ethylpentedrone exceeding 2,000 ng/mL with no measurable decrease over 17 hours of monitoring,[6] suggesting a prolonged half-life.
Pentedrone is metabolized primarily through carbonyl reduction and N-dealkylation. Unchanged pentedrone is largely absent from urine; a reduced alcohol metabolite serves as the primary urinary marker of use.[24] This same metabolite is produced by α-PVP and N-ethylpentedrone, complicating forensic identification.[25]
Pentedrone binds to human serum albumin at specific sites, with the two enantiomers interacting differently with blood proteins.[26] Which liver enzymes metabolize pentedrone has not been established; class-level data for related cathinones indicates involvement of CYP2D6 and CYP2B6.[27]
Neuroscience[edit]
Neuroscience
Where it acts
Pentedrone's dopamine and norepinephrine blockade concentrates its effects in the brain's mesolimbic pathway — the circuit running from the ventral tegmental area to the nucleus accumbens — and in prefrontal cortical regions governing attention and executive function.[2] Increased dopamine in the nucleus accumbens produces the euphoria and reinforcement; increased norepinephrine drives the arousal, alertness, and sympathomimetic peripheral effects. This translates subjectively as focused stimulation with pronounced motivational drive but without the emotional openness produced by serotonin-active compounds.
Addiction and neuroplasticity
Pentedrone induces conditioned place preference in mice, directly demonstrating its rewarding properties.[1] Repeated administration of the closely related N-ethylpentedrone produces robust, long-lasting accumulation of ΔFosB in the striatum — a molecular marker strongly associated with the transition from casual to compulsive drug use.[28]
Alongside this addiction marker, repeated exposure produced striatal dopamine depletion, elevated stress hormones during withdrawal, increased aggression, and impaired social behavior.[28] In cell studies, S-(+)-pentedrone produces greater oxidative damage to dopamine neurons than R-(-)-pentedrone,[19] and class-level evidence links synthetic cathinones to neuroinflammation and transporter damage with repeated use.[29]
Key unknowns include whether the two enantiomers of pentedrone differ in subjective potency or abuse potential in humans — cell data suggests they do,[19] but no human studies exist. Whether the striatal dopamine depletion observed in animal models of repeated use[28] translates to lasting impairment in human users remains unanswered, as no neuroimaging studies have been conducted. No human dose-response curve has been established for any outcome measure.
Subjective Effects[edit]
Pentedrone delivers a narrow-band stimulant experience shaped by its selectivity for dopamine and norepinephrine with minimal serotonin involvement. The result is a focused, task-oriented drive — alert, motivated, and mentally sharp — that intensifies across the dose range into restless overstimulation and anxious hypervigilance. Set and setting strongly determine whether the dopaminergic push manifests as productive focus or jittery agitation, and the short peak creates a pronounced compulsive redosing cycle that can rapidly shift the experience from rewarding to aversive.
The closest experiential comparisons are cocaine and methylphenidate — both dopamine/norepinephrine blockers lacking serotonergic warmth. Users familiar with cocaine will recognize the focused euphoria and abrupt offset; pentedrone's key distinction is a longer aftereffect tail and more pronounced residual dysphoria compared to cocaine's cleaner decline.[5]
Effect Grid
At common doses, pentedrone's full stimulant profile manifests: pronounced cognitive euphoria, strong motivation enhancement, thought acceleration, and marked wakefulness. Focus intensification can produce a driven, task-oriented state. Appetite suppression is strong. Entactogenic effects are notably absent — the experience is primarily dopaminergic rather than serotonergic.
Cardiovascular effects become significant: elevated heart rate, increased blood pressure, and vasoconstriction. Jaw tension (bruxism), sweating, and mydriasis are typical. Body temperature rises modestly. The compulsive redosing urge is prominent at this range due to the short peak duration.
Sleep is impossible for 2–4 hours after the last dose. Aftereffects include residual stimulation, irritability, and potential low mood as dopaminergic effects wane.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Touch enhancement · Tinnitus · Auditory hallucinations · External hallucinations · Shadow people
External hallucinations · Shadow people
Pupil dilation · Dehydration sensation · Dry mouth · Insomnia · Physical fatigue · Restlessness · Excessive sweating · Bruxism · Spontaneous body sensations · Body high · Heart rate perception changes · Muscle tension · Respiratory stimulation · Dizziness · Headache · Nausea · Tingling / electric sensations · Trembling · Vibrations / buzzing · Sexual arousal suppression · Tactile euphoria · Constipation · Involuntary body movements · Motor control impairment · Sexual arousal enhancement · Vomiting · Tactile hallucination
Insomnia · Physical fatigue · Restlessness · Excessive sweating · Bruxism · Spontaneous body sensations · Body high · Heart rate perception changes · Muscle tension · Respiratory stimulation · Dizziness · Headache · Nausea · Tingling / electric sensations · Trembling · Vibrations / buzzing · Sexual arousal suppression · Tactile euphoria · Constipation · Involuntary body movements · Sexual arousal enhancement · Vomiting · Tactile hallucination
Motivation suppression · Focus enhancement · Motivation enhancement · Information processing enhancement · Analysis enhancement · Thought deceleration · Immersion enhancement · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Conceptual thinking · Focus suppression · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Confusion · Thought loops · Cognitive impairment · Thought disorganization · Delirium · Delusions
Information processing enhancement · Analysis enhancement · Thought deceleration · Immersion enhancement · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Conceptual thinking · Focus suppression · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Confusion · Thought loops · Cognitive impairment · Thought disorganization · Delusions
Anxiety · Dysphoria · Emotional enhancement · Emotional lability · Mania
Emotional lability
Sociability enhancement · Social connection · Communication enhancement · Flow state · Automaticity
Automaticity
Timeline
First alerts emerge as mild restlessness and a subtle lift in mood. Physical sensations are minimal — a faint increase in heart rate may be noticeable.
Stimulation builds steadily with increasing alertness, thought acceleration, and rising heart rate. Appetite suppression begins. Mild jaw tension may appear.
Full stimulant effects: pronounced cognitive euphoria, strong motivation enhancement, wakefulness, and appetite suppression. Cardiovascular effects (tachycardia, hypertension) are at their maximum. Compulsive redosing urge is strongest during this phase.
Stimulation gradually recedes. Euphoria fades first, leaving residual wakefulness and mild irritability. Cardiovascular parameters begin normalizing.
Residual effects include lingering wakefulness, mild dysphoria or flatness, and possible difficulty sleeping. Irritability and low mood may persist as dopaminergic tone recovers.
⚠ Do not drive or operate machinery until sleep has been obtained and residual stimulation has fully resolved.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- cocaine · amphetamine · methamphetamine
Toxicity
No lethal dose has been established for pentedrone in humans or animals. No controlled human toxicity studies exist. All safety data derives from cell studies, animal experiments, forensic casework, and case reports involving related compounds.
Liver toxicity
In vitro testing shows pentedrone is significantly more toxic to liver cells than MDMA, through mechanisms including oxidative stress, energy depletion, and programmed cell death.[7] Antioxidants partially reduced cell death in these experiments. Translation to human liver toxicity requires caution, but the findings raise concern for liver injury in heavy or chronic use.
Neurotoxicity
S-(+)-pentedrone produces greater oxidative damage and cell death in dopamine-producing neurons than R-(-)-pentedrone, with oxidative stress as the primary pathway.[19] Pentedrone-class cathinones demonstrate higher toxicity to nerve cells than methamphetamine, with toxicity increasing as the side chain lengthens.[17]
Overheating
N-ethylpentedrone induced slight body temperature increases in mice during repeated dosing.[28] Dangerous overheating is a major class-level concern for synthetic cathinones, with severe cases documented in clinical literature.[30]
Severe intoxication
No confirmed pentedrone-only fatality appears in the peer-reviewed literature. An unverified report references a death involving pentedrone combined with α-PVP causing heart failure.[13] safety citation needed
The most informative case involves N-ethylpentedrone: a man who insufflated the substance presented with blood concentrations exceeding 2,000 ng/mL, severe agitation, paranoid delusions, rapid heart rate, fever, muscle breakdown, kidney failure, and coma requiring intensive care and intubation for 3 days.[6] The treating physicians noted the patient "would most likely have died without intensive care."
A fatal case involving 4-methylpentedrone (a direct ring-substituted derivative) occurred in a chemsex context, with multiple other substances also present.[31]
Expected toxidrome
Based on cathinone class literature and the N-ethylpentedrone case,[6] the expected pattern of toxicity includes:
- Cardiovascular: rapid heart rate, high blood pressure
- Neurological/psychiatric: agitation, paranoia, hallucinations, seizure risk
- Metabolic: muscle breakdown, kidney failure (severe cases)
- Thermoregulatory: dangerous overheating
- Ophthalmological: dilated pupils
No specific antidote exists. Treatment is supportive: benzodiazepines for agitation, active cooling for overheating, aggressive intravenous fluids for muscle breakdown, and intensive care monitoring for severe presentations.[32]
Seek immediate medical attention for: loss of consciousness, chest pain, severe agitation or psychosis, fever exceeding 38.5°C, or seizures. Clinical deterioration can occur rapidly — an initially stable presentation may progress to organ failure within hours.[6]
Psychological risks
Acute psychological adverse effects documented from the cathinone class include anxiety, agitation, irritability, paranoid thinking (particularly at higher doses), and insomnia.[33] The short duration of dopamine-driven effects combined with the reuptake-blocking mechanism creates a compulsive redosing pattern that can escalate psychological distress through sleep deprivation and dopamine depletion cycles.
No data exist on persistent perceptual disturbances or long-term psychiatric effects specific to pentedrone.
Tolerance and dependence
Tolerance develops primarily through DAT downregulation and dopamine depletion. No published data quantify tolerance development for pentedrone specifically; class-level estimates suggest tolerance halves in approximately 5 days and fully resets at approximately 1.5 weeks. inferred Cross-tolerance with other dopamine-targeting stimulants (cocaine, amphetamines, other cathinones) is expected.
Dependence liability is substantial. Pentedrone produces conditioned place preference in mice.[1] The closely related N-ethylpentedrone produces robust ΔFosB accumulation in the striatum — a molecular marker strongly linked to addiction — alongside withdrawal effects including increased aggression, impaired social behavior, elevated stress hormones, and striatal dopamine depletion.[28]
Drug interactions
Noradrenergic potentiation
Combinations with other norepinephrine-active drugs or stimulants risk a noradrenergic crisis — excessive norepinephrine producing severe high blood pressure, rapid heart rate, and cardiovascular collapse. Tramadol is of particular concern: as both an opioid and a serotonin-norepinephrine reuptake inhibitor, it could produce additive effects on norepinephrine while lowering the seizure threshold through two independent mechanisms. safety citation needed
Serotonergic combinations
Combination with MDMA poses additive cardiovascular stimulation with particular risk in warm environments during physical activity. If pentedrone possesses any SERT substrate activity,[21] MDMA-induced serotonin flooding could elevate serotonin syndrome risk. Combination with MAOIs presents severe risk through impaired catecholamine breakdown.
Stimulant stacking
Concurrent use with other stimulants (cocaine, amphetamines, other synthetic cathinones) produces additive cardiovascular strain and overheating risk. Pentedrone has been detected in syringe residues from chemsex sessions alongside multiple other substances,[34] confirming real-world polydrug use.
Alcohol
No specific interaction data exist. The general stimulant-alcohol pattern applies: masking of sedation leading to overconsumption of either substance, compounded by cardiovascular strain.
Detection
Pentedrone does not trigger positive results on standard amphetamine immunoassay screening.[35] Confirmation requires specialized laboratory testing. This evasion of routine drug screening has important implications for emergency treatment and monitoring programs.
Contraindications
Pentedrone's stimulant activity and liver toxicity potential establish several contraindication categories, all inferred from its pharmacology and class-level evidence rather than pentedrone-specific clinical data.
Heart conditions (high blood pressure, coronary artery disease, irregular heartbeat, structural heart disease) represent the highest-risk category under the additional stimulant load. Liver impairment elevates risk given pentedrone's in vitro liver toxicity exceeding that of MDMA.[7] Psychiatric conditions including psychotic disorders and bipolar disorder are relative contraindications, as dopamine stimulation may trigger or worsen psychosis or mania. Seizure disorders are contraindicated given the seizure risk inherent to stimulants. Pregnancy and breastfeeding are absolute contraindications. Concurrent use of MAOIs is absolutely contraindicated due to risk of dangerous blood pressure crisis.
Harm Reduction[edit]
Forms & Identification
Pentedrone typically appears as a white crystalline powder and may be visually indistinguishable from other synthetic cathinones, making laboratory-grade testing essential rather than optional. Standard immunoassay drug panels do not detect pentedrone[35] — a negative screening result provides no safety assurance. The eight positional isomers of pentedrone present identification challenges even for analytical labs,[20] meaning reagent testing can confirm cathinone class membership but cannot definitively distinguish pentedrone from closely related analogues.
Guidelines
- Test every batch. Reagent testing confirms the cathinone class; quantitative analysis (if accessible) addresses purity and identity.
- Set a firm dose and stick to it. Measure with a milligram-precision scale. Eyeballing powder doses is unreliable and dangerous.
- Remove redose material from your environment before taking the first dose. The compulsive redosing drive is pharmacologically inherent, not a willpower failure.
- Stay hydrated but do not overhydrate — aim for regular sips of water rather than large volumes.
- Avoid hot environments and extended physical activity. Overheating is a serious cathinone class risk.
- Set a curfew. Sleep deprivation from stimulant use amplifies anxiety, paranoia, and perceptual disturbances with each missed sleep cycle.
- Have a trusted person aware of what you have taken, when, and how much.
- Eat before dosing. Appetite suppression is pronounced; pre-loading nutrition reduces post-session depletion.
Set & Setting
The dopamine-dominant, serotonin-absent profile makes pentedrone's subjective quality heavily dependent on context. In a calm, task-oriented setting, the stimulation tends toward productive focus; in a chaotic, overheated, or socially pressured environment, the same pharmacology produces anxious hypervigilance and paranoid thinking.
The short peak and abrupt offset create strong compulsive redosing urges — establishing a firm session plan before the first dose is one of the most effective harm reduction measures for this compound class.
Aftercare & integration. The stimulant comedown from pentedrone reflects acute dopamine depletion and sleep disruption. Prioritize sleep above all else — a full sleep cycle is the single most restorative intervention. Eat nutrient-dense meals even if appetite is absent; the appetite suppression outlasts the stimulant effects.
Avoid redosing to manage the comedown. The dysphoria, fatigue, and low motivation following use are time-limited neurochemical effects, not a permanent state. If depression, anxiety, or cravings persist beyond 72 hours, consider professional consultation.
Recovery & Support
Pentedrone's compulsive redosing pattern and dopamine-depleting profile can escalate into dependent use patterns, particularly during binge sessions. If use has become difficult to control, or if sessions are extending beyond planned limits, this signals a pattern that benefits from external support.
SMART Recovery and stimulant-specific support groups address the cognitive and behavioral patterns characteristic of cathinone dependence. A healthcare provider experienced with stimulant use disorders can assess whether pharmacological or therapeutic support is appropriate. Harm reduction services in many regions offer confidential, non-judgmental guidance — seeking help is not contingent on committing to abstinence.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable stimulant effects — jitteriness, mild anxiety, rapid heartbeat — are distinct from medical emergencies. Seek immediate help for: chest pain, seizure, loss of consciousness, body temperature hot to the touch through clothing, severe paranoid psychosis (loss of contact with reality), or uncontrollable agitation.
Immediate steps:
- 1. Call emergency services.
- 2. Move the person to a cool, quiet environment.
- 3. If unconscious but breathing, place in the recovery position.
- 4. Do not restrain unless immediate danger of self-harm — restraint worsens overheating and agitation.
- 5. Remove excess clothing and apply cool (not ice-cold) water if overheating is suspected.
- 6. Stay with the person until help arrives.
What to tell the dispatcher: Name the substance (synthetic cathinone / pentedrone), estimated amount and time of use, current symptoms, and whether other substances were taken. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Clinical deterioration can be rapid — initial presentation may appear non-critical before progressing to organ failure within hours.[6]
Legal Status[edit]
Legal status
Pentedrone is internationally controlled. The WHO Expert Committee on Drug Dependence reviewed pentedrone at its 38th meeting in 2016 and recommended scheduling. It was subsequently placed in UN Psychotropic Schedule II.[13][36] Prior to substance-specific scheduling in many jurisdictions, pentedrone served as a scheduling-circumvention compound — vendors marketed it as a replacement for recently controlled cathinones.[9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary emergency Schedule I from 27 February 2014;[11] extended 2016;[12] permanently placed March 2017[4] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under generic cathinone amendment effective 16 April 2010[8] |
| Germany | Anlage II (authorized trade only) | Specific scheduling date not confirmed from primary sourcescitation needed |
| China | Controlled substance | Scheduled October 2015[13] |
| Australia | Controlled substance | Listed in ODC database; specific scheduling date not confirmedcitation needed |
| Canada | Controlled substance | Confirmed controlled; specific scheduling date not confirmedcitation needed |
| Brazil | F2 | Controlled; specific provision not confirmed[13] |
| Czech Republic | Banned | Specific provision not confirmed[13] |
| United Nations | Psychotropic Schedule II | Following WHO ECDD 38th meeting recommendation (2016)[13] |
Prior to the 2014 emergency scheduling in the United States, pentedrone would have been subject to the Federal Analogue Act as a structural analog of cathinone and methcathinone. The scheduling of synthetic cathinones under the Controlled Substances Act involves coordination between HHS, FDA, NIDA, and the DEA.[37]
references
- [1] ^abcdefDuart-Castells L, Nadal-Gratacós N, Muralter M, Puster B, Berzosa X, Estrada-Tejedor R, Niello M, Bhat S, Pubill D, Camarasa J, Sitte HH, Escubedo E, López-Arnau R (2021) Role of amino terminal substitutions in the pharmacological, rewarding and psychostimulant profiles of novel synthetic cathinones. — Neuropharmacology doi:10.1016/j.neuropharm.2021.108475
- [2] ^abcdSimmler LD, Rickli A, Hoener MC, Liechti ME (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones — Neuropharmacology doi:10.1016/j.neuropharm.2013.11.008
- [3] ^abMaheux CR, Copeland CR (2012) Chemical analysis of two new designer drugs: buphedrone and pentedrone — Drug testing and analysis doi:10.1002/dta.385
- [4] ^abcDrug Enforcement Administration (2017) Schedules of Controlled Substances: Placement of 10 Synthetic Cathinones Into Schedule I. Final rule. — Federal Register PMID:28355044
- [5] ^abDrevin G, Gaulier JM, Hakim F, et al. (2024) Synthetic cathinones in drug-facilitated sexual assault: A case report involving N-ethylpentedrone — Forensic science international doi:10.1016/j.forsciint.2024.112030
- [6]